Recruiting

Observational Study

Sponsor:

Immune Oncology Research Institute

Code:

NCT05711992

Conditions

Embryonal Tumor

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of rare diseases that need further research. This international registry aims to establish a large multicenter database of pediatric and young adult patients with rare embryonal tumors of the central nervous system and describe the clinical presentations, diagnostics, treatment regimens, and outcomes. Embryonal tumors with multilayered rosettes (ETMR), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, and CNS tumor with BCOR internal tandem duplication are extremely rare embryonal tumors some of which were first described in the last edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Objectives of the registry are 1) to evaluate prognostic factors, 2) to identify diagnostic and treatment gaps, 3) to investigate the characteristics and outcome of the disease with different treatment regimens, and 4) to generate data-based prospective diagnostic and treatment recommendations.

Conditions

Embryonal Tumor

Study ID

NCT05711992

Start date

Feb 1, 2023

Status verified date

May, 2025

Completion date

Feb, 2033

Anticipated

Primary completion date

Feb, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients diagnosed with rare embryonal tumors of CNS since 01.01.2010:

  • ETMR (including embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma (EBL) and medulloepithelioma (MEPL) which were previously classified as CNS-PNETs)
  • FOXR2-activated CNS neuroblastoma
  • cribriform neuroepithelial tumor
  • CNS tumor with BCOR internal tandem duplication
  • all patients diagnosed with neuroblastoma and ganglioneuroblastoma with no molecular genetic tests available
  • Patients ≤ 25 years of age
  • Signed informed consent form for prospective patients ≥ 18 years of age
  • Signed parental permission and child assent forms for prospective patients < 18 years of age

Exclusion Criteria:

• CNS metastases of extracranial embryonal tumors

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • 3-year overall survival [ Time Frame: 3 years ]
  • 5-year overall survival [ Time Frame: 5 years ]

Central Contacts and Locations

Locations

Children's Hospital of Eastern Ontario (CHEO)

Recruiting

Ottawa, Canada, K1H 8L1

Contacts

Consolato M Sergi, MD, PhD, MPH

csergi@cheo.on.ca

More Information

Sponsor

Immune Oncology Research Institute

Last update posted

May 8, 2025

Last verified

May, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Immune Oncology Research Institute on 2025-05-08.